Article
Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
PloS one - 1 Jan 2012
Tabara Keisuke, Kanda Rina, Sonoda Kahori, Kubo Takuya, Murakami Yuichi, Kawahara Akihiko, Azuma Koichi, Abe Hideyuki, Kage Masayoshi, Yoshinaga Aki, Tahira Tomoko, Hayashi Kenshi, Arao Tokuzo, Nishio Kazuto, Rosell Rafael, Kuwano Michihiko, Ono Mayumi
Abstract excerpt
Non-small-cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations attains a meaningful response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired resistance to EGFR-TKIs could affect long-term outcome in almost all patients. To identify the potential mechanisms of resistance, we established cell lines resistant to EGFR-TKIs from the human lung cancer cell lines PC9 and11-18, which...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.